Becton Dickinson's BD Rhapsody™ System Reaches 1,000 Installations, Advancing Single-Cell Multiomics
- Becton Dickinson installed its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, enhancing single-cell multiomics research.
- The BD Rhapsody™ System enables in-depth analysis of immune responses and inflammation in critically ill patients.
- Since 2017, the system has been referenced in over 700 publications, showcasing its impact on biomedical research.
BD Rhapsody™ System Milestone Highlights Advances in Single-Cell Multiomics
Becton, Dickinson and Company (BD), a leading force in medical technology, marks a significant milestone with the installation of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, University of Cambridge, on September 17, 2025. This sophisticated instrument is pivotal for single-cell multiomics, allowing researchers to analyze hundreds of thousands of individual cells concurrently. The BD Rhapsody™ System not only enhances the depth of insights into cellular functions but also seeks to transform understanding in critical areas such as immune response and inflammation, particularly in critically ill patients.
Dr. Andrew Conway Morris, an associate professor at Addenbrooke's, emphasizes the system's transformative potential in advancing research on immune cell signaling pathways. By unraveling the complexities of how these pathways operate, researchers aim to translate their findings into improved therapeutic strategies. The ability to conduct nuanced multiomic analyses positions the BD Rhapsody™ System as an essential tool for modern biomedical research, enabling scientists to explore cellular behavior and interactions in unprecedented detail.
Since its launch in 2017, the BD Rhapsody™ System has gained significant traction within the scientific community, being referenced in over 700 peer-reviewed publications. The most recent iteration, introduced in 2023, boasts enhanced capabilities with innovative microwell-based cartridge technology and proprietary molecular indexing, which streamline sample processing and cell capture. This evolution not only accelerates research insights but also integrates seamlessly with other BD instruments, such as the BD FACSDiscover™ S8 Cell Sorter, thereby enriching the cell sorting and analysis workflows.
In addition to this milestone, Ranga Partha, PhD, Vice President of Global Marketing and Strategic Growth at BD Biosciences, notes the strong demand for a high-performing single-cell platform. He highlights the balance that the BD Rhapsody™ System achieves between robust multiomic assays and data quality at an accessible cost per cell. This demand reflects the growing importance of advanced medical technologies in driving innovative research and improving patient outcomes in healthcare.
As BD continues to innovate within the field of medical technology, the successful deployment of the BD Rhapsody™ System underscores the company's commitment to enhancing scientific capabilities and supporting groundbreaking research endeavors across the globe. The integration of cutting-edge technology with practical research applications positions BD as a pivotal player in advancing healthcare solutions.